OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate.
暂无分享,去创建一个
[1] T. Stamey,et al. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.
[2] R. Thomas,et al. Aid to accurate clinical staging-histopathologic grading in prostatic cancer. , 1982, The Journal of urology.
[3] K. Griffiths,et al. Pathological and clinical associations of Ki‐67 defined growth fractions in human prostatic carcinoma , 1992, The Prostate.
[4] D. Chalbos,et al. Expression of the progestin-induced fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridization. , 1990, Journal of the National Cancer Institute.
[5] D. Chan,et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.
[6] Galina Pizov,et al. Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.
[7] C. Gatsonis,et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. , 1990, The New England journal of medicine.
[8] H. Kanetake,et al. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma , 1991, The Prostate.
[9] J. Moul,et al. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. , 1993, The Journal of urology.
[10] V. Reuter,et al. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma , 1993, Cancer.
[11] D. Neal,et al. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. , 1992, The Journal of urology.
[12] S. Hilsenbeck,et al. p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.
[13] P. Carroll,et al. Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. , 1993, The Journal of urology.
[14] M. Brawer,et al. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity , 1994, Cancer.
[15] J. Oesterling,et al. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.
[16] G. Pasternack,et al. Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator. , 1992, American journal of clinical pathology.
[17] L. Jacobs,et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[18] S. Piantadosi,et al. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. , 1989, The New England journal of medicine.
[19] R. Sadasivan,et al. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. , 1993, The Journal of urology.
[20] E. Gelmann,et al. p53 oncogene mutations in human prostate cancer specimens. , 1994, The Journal of urology.